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Regulation of inositol 1,4,5-trisphosphate receptors by trans- accepted that the pathogenesis of diabetic nephropathy
forming growth factor-b: Implications for vascular dysfunction is closely associated with altered regulation of vascular
in diabetes. Diabetes in its early stages is associated with en- function at the glomerular level [2]. Although TGF-b ishanced glomerular blood flow and systemic vasodilation. Possi-
not thought to have direct effects on vascular tone, weble consequences of enhanced glomerular blood flow are glo-
considered the possibility that there may indeed be anmerular hypertrophy, increased shear stress, and subsequent
glomerulosclerosis. The prosclerotic cytokine, transforming important link between up-regulation of TGF-b in dia-
growth factor-beta (TGF-b), has been well established to play betic glomeruli and the altered glomerular hemodynam-
a key role in mesangial matrix accumulation in diabetes; how-
ics characteristic of diabetes. In the present review, weever, its role in regulating vascular tone has not been studied in
discuss the potential role of TGF-b in mediating thedepth. Earlier studies have demonstrated that vascular smooth
muscle cells and mesangial cells pretreated with TGF-b have vascular effects of diabetes.
impaired calcium mobilization to inositol 1,4,5-trisphosphate In the early stages of diabetic kidney disease, glomeru-
(IP3) generating agonists, such as platelet-derived growth factor lar hypertrophy and increased glomerular blood flow(PDGF) and Angiotensin II (Ang II). We postulated that this
occur. The latter is thought to be primarily mediated byaction of TGF-b may be caused by regulation of the key intra-
dilation of the afferent arteriole [2–4]. In addition, it iscellular calcium channel, the inositol 1,4,5-trisphosphate recep-
tor (IP3R). Mesangial and smooth muscle cells primarily con- likely that the glomerular mesangial cell plays an impor-
tain the types I IP3R and III IP3R isoforms. Short-term exposure tant role, as this cell type has smooth muscle-like proper-
of mesangial cells to TGF-b (15–60 min) leads to phosphoryla-
ties, and due to its particular location at the base oftion of the type I IP3R at specific serine residues. Long-term
the glomerular capillary loops it is associated with theexposure of mesangial cells to TGF-b (24 hours) leads to down-
regulation of protein levels of both types I and III IP3Rs as contractile state of the glomerulus [5]. Although numer-
assessed by Western blot and confocal analysis. Permeabiliza- ous studies have evaluated the determinants of glomeru-
tion of cells and exposure to IP3 leads to impaired calcium lar blood flow in the intact diabetic animal via a varietymobilization if cells are pretreated with TGF-b. As an in vivo
of methods [6–9], for the purpose of this review we willcorrelation, we found that streptozotocin-induced diabetic rats
and mice have reduced renal type I IP3R expression. By immu- focus primarily on studies that have evaluated the contri-
nostaining, we found reduction of type I IP3R in glomerular bution of glomerular-derived factors to this process.
cells and arteriolar smooth muscle cells of the diabetic rat
kidney. Treatment of diabetic mice with a neutralizing anti-
TGF-b antibody completely prevents diabetic glomerular hy- MITOGENIC AND VASOCONSTRICTIVE
pertrophy. We conclude that the vascular dysfunction of diabe- FACTORS IN THE GLOMERULUS OF THEtes leading to glomerular hypertrophy is mediated, in part, by
DIABETIC RATTGF-b-induced regulation of IP3Rs.
Characterization of various vasoactive and growth fac-
tors in the diabetic kidney have revealed interesting in-
Transforming growth factor-beta (TGF-b) is now con- formation. There is increased expression of the potent
sidered a critical cytokine involved in mediating excess mesangial cell mitogen, platelet-derived growth factor
mesangial matrix accumulation in diabetic nephropathy (PDGF) chain in the glomeruli of diabetic rats [10]. Up-
[1]. In addition to mesangial matrix accumulation, it is regulation of PDGF-B chain mRNA begins at week 4
and persists at week 24 of diabetes. Other potential mes-
angial cell mitogens such as hepatocyte growth factor
(HGF) [11, 12], basic fibroblast growth factor (bFGF)Ó 2000 by the International Society of Nephrology
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[10], epidermal growth factor (EGF) [13], and insulin- One plausible theory to explain these findings is to
assume that a central process common to mesangial celllike growth factor (IGF) [14] or their receptors or binding
proteins have also been found to be increased in renal mitogens and vasoconstrictors is impaired and that this
process prevents mesangial and smooth muscle cells fromtissue at various times during the early phases of diabetic
kidney disease. Thus, a marked degree of mesangial cell maximally responding to the factors surrounding them.
For example, PDGF, epidermal growth factor (EGF),proliferation might be expected during this early stage
of diabetes. However, by light microscopy mesangial cell insulin-like growth factor (IGF), Ang II, and ET all share
a common pathway to stimulate production of inositolproliferation is not a prominent feature in the glomeruli
from patients with recently diagnosed type 1 diabetes 1,4,5-trisphosphate (IP3) through phospholipase C (PLC)
isoforms [27]. The mitogenic factors primarily stimulate[15]. In addition, in experimental diabetes there is a 50%
increase in glomerular volume in the first 2 weeks of PLC-g; whereas the vasoconstrictors stimulate PLC-b.
In either case, generation of IP3 leads to the releasediabetes [16] despite a lack of increase in 3H-thymidine
incorporation into the glomeruli during this phase [17]. of intracellular calcium through binding of IP3 to IP3
receptors (IP3R) located in the endoplasmic reticulumIt could be concluded that the proliferative response of
mesangial cells to PDGF and other mitogens is greatly and perhaps other calcium-sequestering sites. If IP3-
mediated calcium release is inhibited in the diabetic mi-attenuated during the development of diabetic glomeru-
lar hypertrophy. lieu, one should expect to see a decreased release of
calcium to the various IP3-generating agonists. Support-Various classical vasoactive factors have also been
evaluated in the glomeruli of diabetic rats. Given the ing this hypothesis are the results of studies by Mene
et al [28] and Hadad et al [29]. These investigators foundknown finding of increased glomerular volume and in-
creased glomerular blood flow, one might assume that that when mesangial cells are cultured in high glucose or
derived from the glomeruli of diabetic rats, an impairedthere would be a relative increase in vasodilators and a
decrease in vasoconstrictors. However, the data thus far release of intracellular calcium occurs in response to
are inconclusive. Although the importance of the renin- various vasoconstrictors, including AngII, vasopressin,
angiotensin (Ang II) system in the development of glo- and norepinephrine. Given that TGF-b is stimulated by
merular hypertrophy is unquestioned, there is no consen- high glucose in mesangial cell culture and in the glomer-
sus whether increased activation of this system occurs in uli of diabetic rats, we postulated a role for TGF-b in
early diabetes [18]. However, the potent vasoconstrictor regulating intracellular calcium in relation to diabetic
endothelin (ET) has clearly been found to be increased vascular dysfunction.
in diabetic glomeruli at the mRNA level [19]. With re-
spect to vasodilators, nitric oxide (NO) has been exam-
ROLE OF TGF-b IN REGULATINGined in isolated glomeruli from diabetic rats as well as
INTRACELLULAR CALCIUMin mesangial cells cultured in the diabetic milieu. Cyclic
TGF-b inhibits intracellular calcium release after bothGMP production in response to NO production via the
short-and long-term exposure. We have described thatconstitutive pathway appears to be inhibited in diabetic
mesangial cells pretreated with TGF-b for 15–30 minglomeruli [20], although other studies have determined
have inhibition of PDGF-induced calcium release [30].that stimulation of the inducible form of NO synthase
In addition, short-term TGF-b treatment also inhibitsis enhanced when mesangial cells are cultured in high
calcium mobilization in mesangial cells in response toglucose [21, 22]. In the intact diabetic animal, several
EGF (Sharma, unpublished data). Zhu et al demon-groups have found an elevated basal production of NO
strated a similar process in vascular smooth muscle cellsmetabolites in the urine of diabetic rats [23, 24]. Reports
[31]. In their study, after a period of 15 minutes of TGF-bregarding the role of atrial natriuretic peptide (ANP) in
exposure, the elevation in intracellular calcium in re-diabetic kidney disease are also somewhat inconsistent.
sponse to Ang II was significantly attenuated. Given thatThere appears to be an increase in circulating ANP levels
the mitogens PDGF and EGF as well as the vasoconstric-in poorly controlled diabetic rats [25] but not in moder-
tor Ang II all stimulate calcium mobilization throughately controlled diabetic rats [26]. Of note, only the latter
IP3R, we postulated that the mechanism underlying thisdiabetic rats consistently demonstrate glomerular hyper-
characteristic of TGF-b in both these cell types is relatedtrophy and increased glomerular blood flow [3]. Al-
to the regulation of IP3R.though only a few of the many studies in this field have
Primarily, three major isoforms of the IP3R exist inbeen cited, it seems fair to state that based on the accu-
mammalian cells [32]. Mesangial cells and vascular smoothmulated data regarding the relative levels of vasocon-
muscle cells in the kidney predominantly express typesstrictors and vasodilators it does not appear evident that
I and III IP3R as demonstrated by immunostaining ofa state of glomerular hypertrophy and vasodilation
normal rat kidney [33]. We found that short-term expo-should predominate over vasoconstriction in the diabetic
state. sure of mesangial cells to TGF-b (15 to 30 minutes) was
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Fig. 1. Reduced glomerular type I IP3R pro-
tein levels in diabetes. Glomerular protein was
isolated from normal rats, diabetic rats with
hyperglycemia receiving low-dose insulin, and
diabetic rats treated with high-dose insulin to
achieve near euglycemia. 20 mg of protein was
resolved on a 7% SDS-PAGE gel and immu-
noblotted with antibody to type I IP3R, as
previously described [37].
sufficient to induce phosphorylation of type I IP3R on curing in vivo to inhibit mesangial cell response to mito-
gens and inhibit vascular smooth muscle cell responsespecific serine residues [34]. It is likely that the cyclic
adenosine monophosphate (cAMP)-dependent serine- to vasoconstrictors.
threonine kinase, protein kinase A (PKA), plays a role
in TGF-b-induced phosphorylation of the type I IP3R as REGULATION OF IP3R ISOFORMSthe sites in the type I IP3R subject to PKA phosphoryla- IN DIABETES
tion are the same sites phosphorylated by TGF-b treat-
We have recently evaluated the expression of the typement [34]. In addition, synthetic peptides that encode
I IP3R isoform in the kidney of diabetic rodents [37]. Infor the PKA-sensitive phosphorylation sites of type I
both the streptozotocin-induced diabetic mouse and theIP3R are phosphorylated by lysates from TGF-b–treated
streptozotocin-induced diabetic rat, we found decreasedmesangial cells and this kinase activity is completely
expression of type I IP3R at the protein and mRNAblocked by the PKA inhibitor peptide (PKI) [34]. Fur-
levels. Reduced type I IP3R levels were associated withthermore, we have demonstrated in mesangial cells that
a concurrent increase in TGF-b1 levels. By immunostain-TGF-b stimulates the activation of PKA after 5 to 15
ing, we found that type I IP3R protein was primarilyminutes [35]. We therefore postulate that TGF-b–
located in the glomerulus and in vascular smooth muscleinduced phosphorylation of type I IP3R inhibits IP3R
cells of glomerular arterioles. The degree of intensity ofsensitivity to IP3 and thus interferes with calcium release
immunostaining for the type I IP3R was reduced in thein response to an agonist that elevates IP3 levels.
diabetic rat but restored if the diabetic rats were treatedIn addition to the short-term effects of TGF-b, we
with high doses of insulin to prevent hyperglycemia. Sim-also evaluated whether chronic exposure of cells to TGF-b
ilar results were found by Western blot analysis withaffects levels of IP3R isoforms. In mesangial cells, we
protein isolated from glomeruli of normal, diabetic, andrecently found that TGF-b treatment for 24 hours de-
diabetic rats treated with high dose insulin (Fig. 1).creased the levels of both types I and III IP3R isoforms at
Expression of IP3R isoforms in tissues subject to end-the protein level [36]. Subsequent exposure of mesangial
organ damage of diabetes has not been clearly described.cells to agonists such as EGF or PDGF led to a marked
A recent study in pancreatic islets did demonstrate regu-inhibition of calcium release. To test directly whether
lation of IP3R isoforms by glucose and suggested a rolethe impaired calcium release was at the level of the IP3R,
for IP3R regulation in mediating islet dysfunction in dia-we permeabilized the cells and assessed IP3 sensitivity.
betes [38]. With regard to systemic vascular dysfunctionThe cells treated with TGF-b had a 50% inhibition of
in diabetes, several studies have demonstrated an im-IP3-mediated calcium release in response to IP3 (400 nM).
paired vasoconstrictor response in diabetic animals. Dia-This would likely correspond to the maximal intracellu-
betic rats have an impaired pressor response to vasocon-lar levels of IP3 produced in response to PDGF, EGF,
strictors compared with normal or hypertensive rats [39].or Ang II. Thus, we conclude that chronic exposure of
Contraction of the thoracic aorta to endothelin is im-mesangial cells to TGF-b will lead to down-regulation
paired in diabetic rats [40]. In preliminary studies, weof IP3R isoforms, impaired IP3 sensitivity of the cell, and
found that aortic rings from diabetic rats had impairedconsequently decreased calcium release to IP3-mobiliz-
contractile response to Ang II and this was associateding agonists. Because TGF-b is stimulated in the diabetic
kidney, we postulated that a similar process may be oc- with decreased expression of types I and III IP3R iso-
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forms [41]. Thus, it is likely that vascular dysfunction in has been found to be stimulated in practically all progres-
sive glomerular disorders. Therefore, if an importantdiabetes, involving systemic circulation as well as renal
microcirculation, may be closely related to the expres- characteristic of TGF-b is to influence glomerular hemo-
dynamics, a comprehensive understanding of this processsion pattern of the IP3R isoforms.
will be of great relevance in designing therapeutic regi-
mens to combat progressive renal disease.ROLE OF TGF-b IN DIABETIC
GLOMERULAR HYPERTROPHY
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